US › Healthcare

Verastem Inc (VSTM)

US · Healthcare · Biotechnology

$5.81+2.11%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$18.7M
Net profit
$-36.6M
Profit YoY
+29.8%
EPS
$-0.43
EPS estimate
$-0.47
Net margin
-196.0%

EPS came in at -0.43 against a street estimate of -0.47 — a beat of 8.5%.

Key statistics

Market cap
$500.0M
Forward P/E
0.0
P/B
6.23
Book value
$0.93
EPS (TTM)
$-2.52
52-week high
$11.25
52-week low
$3.43
50-day MA
$4.69
200-day MA
$6.44
Beta
0.29

Analyst view

Analysts rate Verastem Inc a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $15.00.

Shareholding

Insiders
0.93%
Institutions
98.55%

Largest institutional holders

FundStake
RTW INVESTMENTS, LLC7.48%
BlackRock Inc7.05%
Deep Track Capital, LP6.53%
Armistice Capital, LLC5.23%
Nantahala Capital Management, LLC4.08%
State Street Corp4.00%
Vanguard Capital Management, LLC3.78%
Stonepine Capital Management Llc3.76%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Verastem Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.